News >

Larotrectinib Success Underscores Need for NGS to Detect TRK Fusion-Positive Cancers

Jessica Hergert
Published: Wednesday, Sep 04, 2019

Dr Alexander Drilon

Alexander Drilon, MD
Larotrectinib (Vitrakvi) has shown promising activity in patients with TRK fusion–positive cancers who also have brain metastases or primary central nervous system (CNS) tumors, said Alexander Drilon, MD. Results from 2 clinical trials further underscore the need for expanded testing for these fusions across all tumor types.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication